StockDriftsStockDriftsTop 4 Foresite Capital Management Iii, Llc Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| ASND | Ascendis Pharma A/S | 36.44% | 133.7K | $14K | new | — | 2022-09-30 | |
| VRNA | Verona Pharma PLC. | 29.98% | 1.11M | $11K | new | — | 2022-09-30 | |
| NTRA | Natera, Inc. | 18.41% | 159.2K | $7K | new | — | 2022-09-30 | |
| CBAY | Cymabay Therapeutics, Inc. | 15.17% | 1.64M | $6K | new | — | 2022-09-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative |
|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — |
| Top 20 Holdings Unweighted | — | — | — | — |
Foresite Capital Management Iii, Llc reports $37.88K in US-listed equity holdings across 4 positions in its most recent 13F filing. Its largest disclosed positions are ASND (36.4%), VRNA (30.0%) and NTRA (18.4%). Figures reflect the Q3 2022 filing.
Sign up free to track Foresite Capital Management Iii, Llc, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Foresite Capital Management Iii, Llc’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 1645157). View Foresite Capital Management Iii, Llc’s 13F filings on SEC